News
CRMD
7.05
+0.43%
0.03
CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade)
Seeking Alpha · 1d ago
Weekly Report: what happened at CRMD last week (0323-0327)?
Weekly Report · 4d ago
Weekly Report: what happened at CRMD last week (0316-0320)?
Weekly Report · 03/23 09:32
Weekly Report: what happened at CRMD last week (0309-0313)?
Weekly Report · 03/16 09:31
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead
TipRanks · 03/11 00:08
Weekly Report: what happened at CRMD last week (0302-0306)?
Weekly Report · 03/09 09:32
CorMedix Reaffirms DefenCath 2027 Sales and Outlook
TipRanks · 03/06 22:30
CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
TipRanks · 03/06 22:20
CorMedix price target lowered to $13 from $15 at Leerink
TipRanks · 03/06 17:05
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Altimmune (ALT) and Cormedix (CRMD)
TipRanks · 03/06 13:40
Cormedix (CRMD) Receives a Buy from RBC Capital
TipRanks · 03/06 12:37
CorMedix Price Target Cut to $14.00/Share From $15.00 by Needham
Dow Jones · 03/06 10:59
CorMedix Is Maintained at Buy by Needham
Dow Jones · 03/06 10:59
CorMedix Q4 Revenue Improves; Reaffirms FY26 Outlook; Plans To Report Phase III REZZAYO Data In Q2
NASDAQ · 03/06 07:25
Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness
TipRanks · 03/05 20:25
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration
Seeking Alpha · 03/05 19:56
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)
TipRanks · 03/05 16:30
CorMedix nears an 11-month low after earnings miss
Seeking Alpha · 03/05 16:00
CORRECTION: Cormedix Affirms FY2026 Sales Guidance of $300.000M-$320.000M
Benzinga · 03/05 13:25
Cormedix Earnings Review: Q4 Summary
Benzinga · 03/05 13:24
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.